Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Roderich, Schwarz"'
Autor:
Leonard R. Henry, MD, MBA, FACS, Jun Li, PhD, Cletus Arciero, MD, FACS, Urs W. von Holzen, MD, MBA, FACS, Roderich Schwarz, MD, PhD, FACS, Ismail Jatoi, MD, PhD, FACS
Publikováno v:
Annals of Surgery Open, Vol 4, Iss 1, p e236 (2023)
Background:. Better cancer-related outcomes are associated with physicians and hospitals with higher case volume. This serves as an incentive to refer patients requiring complex cancer operations to large referral centers, which may require increased
Externí odkaz:
https://doaj.org/article/a813eb5f1ab140c1bbb38310dad74c1f
Publikováno v:
Cancer Research. 83:480-480
Objective: Cholangiocarcinoma (CCA) is a highly aggressive biliary tract cancer (BTC). CCAs are divided into three subtypes: intrahepatic (iCCA, 10-20%), perihilar (pCCA, 50-60%) or distal (dCCA, 20-30%). CCA has a very poor prognosis with a 5-year s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7f2cc75fce307ab811741f9c4dbea5c
https://doi.org/10.1158/1538-7445.am2023-480
https://doi.org/10.1158/1538-7445.am2023-480
Autor:
Daniel Kagedan, Roderich Schwarz, Jillianna Wasiura, Nikolaos Almyroudis, Robin Patel, Brahm H Segal, Katherine M Mullin
Publikováno v:
Open Forum Infectious Diseases
Background Clostridioides difficile infection rates are subject to infection prevention surveillance as a quality measure within the hospital setting. A large spike in Clostridioides difficile infections in post-operative patients, the majority of wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1574a93daa25d3ae1face22d22c2602a
https://doi.org/10.1093/ofid/ofaa439.1064
https://doi.org/10.1093/ofid/ofaa439.1064
Abstract 289: MET activation mediates lapatinib resistance in experimental esophageal adenocarcinoma
Autor:
Md Sazzad Hassan, Fiona Williams, Lucia Petrova, Niranjan Awasthi, Margaret Schwarz, Roderich Schwarz, Urs von Holzen
Publikováno v:
Cancer Research. 79:289-289
Introduction: A major target for esophageal adenocarcinoma (EAC) therapies is the human epidermal growth factor receptor 2 (HER2). Unfortunately, patients treated with lapatinib, a dual EGFR and HER2 inhibitor, frequently develop resistance. Lapatini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4085737e733acad8314c8a62c494b3d6
https://doi.org/10.1158/1538-7445.am2019-289
https://doi.org/10.1158/1538-7445.am2019-289
Autor:
Robert J, Morgan, James H, Doroshow, Timothy, Synold, Dean, Lim, Stephen, Shibata, Kim, Margolin, Roderich, Schwarz, Lucille, Leong, George, Somlo, Przemyslaw, Twardowski, Yun, Yen, Warren, Chow, Paul, Lin, Benjamin, Paz, David, Chu, Paul, Frankel, Susan, Stalter
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(16 Pt 1)
The purpose of this Phase I study was to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of i.p. docetaxel and to determine the peritoneal pharmacokinetics and pharmacological advantage of this agent.Twenty-one patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0f83207ae51f23ffa09265e636b85d3a
https://pubmed.ncbi.nlm.nih.gov/14676112
https://pubmed.ncbi.nlm.nih.gov/14676112